Minerva Neurosciences' Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting

Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trialData also presented from Phase IIA trials with MIN-101 and MIN-117 WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Minerva...

London, 05/12/2016 (informazione.it - comunicati stampa - salute e benessere)